國家衛生研究院 NHRI:Item 3990099045/10061
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 858839      Online Users : 815
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10061


    Title: Predictors of survival in esophageal squamous cell carcinoma with pathologic major response after neoadjuvant chemoradiation therapy and surgery: The impact of chemotherapy protocols
    Authors: Li, CY;Huang, PM;Chu, PY;Chen, PM;Lin, MW;Kuo, SW;Lee, JM
    Contributors: National Institute of Cancer Research;Institute of Molecular and Genomic Medicine
    Abstract: Tumor recurrence is an important problem threatening esophageal cancer patients after surgery, even when they achieve a pathologic major response (pMR) after neoadjuvant concurrent chemoradiation therapy (CCRT). The predictors related to overall survival and disease progression for these patients remain elusive. We aimed to identify factors that predict disease progression and overall survival in esophageal squamous cell carcinoma (SCC) patients who achieve a pMR after neoadjuvant CCRT followed by surgery. We conducted a retrospective study to analyze the factors influencing survival and disease progression after esophagectomy for esophageal cancer patients who had a major response to CCRT, which is defined by complete pathological response or microscopic residual disease without lymph node metastasis. From our study cohort, 285 patients underwent CCRT and subsequent esophagectomy; 171 (60%) of these patients achieved pMR. After excluding patients with lymph node metastases, incomplete clinical data, and adenocarcinomas, we enrolled 117 patients in this study. We found that the CCRT regimen was the only factor that influenced overall survival. The overall survival of the patients receiving taxane-incorporated CCRT was superior to that of patients receiving traditional cisplatin and 5-fluorouracil (PF) (P = 0.011). The CCRT regimen can significantly influence the clinical outcome of esophageal SCC patients who achieve pMR after neoadjuvant CCRT and esophagectomy. Incorporation of taxanes into cisplatin-based CCRT may be associated with prolonged survival.
    Date: 2016-10
    Relation: BioMed Research International. 2016 Oct;2016:Article number 6423297.
    Link to: http://dx.doi.org/10.1155/2016/6423297
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000385105000001
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84991334124
    Appears in Collections:[Others] Periodical Articles
    [Others] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB27777949.pdf1336KbAdobe PDF426View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback